Design of a miRNA sponge for the miR-17 miRNA family as a therapeutic strategy against vulvar carcinoma

Molecular and Cellular Probes

Volumn 29, Issue 6, 2015, Pages 420-426

  de Melo Maia, Beatriz ^a,b   Ling, Hui ^b   Monroig, Paloma ^b   Ciccone, Maria ^b   Soares, Fernando A ^a   Calin, George A ^b   Rocha, Rafael M ^a  

^a A C CAMARGO CANCER CENTER   (Brazil)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

MicroRNA sponges; MiR 17 family; Vulvar cancer

Indexed keywords

MICRORNA; MICRORNA 17; UNCLASSIFIED DRUG; MIRN17 MICRORNA, HUMAN;

ARTICLE; CANCER PATIENT; CONTROLLED STUDY; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LUCIFERASE ASSAY; MOLECULAR CLONING; MULTIGENE FAMILY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RNA SEQUENCE; TUMOR INVASION; VULVA CARCINOMA; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; MOLECULARLY TARGETED THERAPY; PROCEDURES; SYNTHESIS; TUMOR CELL LINE; VULVAR NEOPLASMS;

CELL LINE, TUMOR; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN VITRO TECHNIQUES; MICRORNAS; MOLECULAR TARGETED THERAPY; MULTIGENE FAMILY; VULVAR NEOPLASMS;

EID: 84951573487     PISSN: 08908508     EISSN: 10961194     Source Type: Journal    
DOI: 10.1016/j.mcp.2015.08.002     Document Type: Article

References (38)

1. Lee R.C., Feinbaum R.L., Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993, 75(5):843-854.
2. Wightman B., Ha I., Ruvkun G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell 1993, 75(5):855-862.
3. Creighton C.J., Nagaraja A.K., Hanash S.M., Matzuk M.M., Gunaratne P.H. A bioinformatics tool for linking gene expression profiling results with public databases of microRNA target predictions. RNA 2008, 14(11):2290-2296.
4. Kunej T., Godnic I., Horvat S., Zorc M., Calin G.A. Cross talk between microRNA and coding cancer genes. Cancer J. 2012, 18(3):223-231.
5. Betel D., Wilson M., Gabow A., Marks D.S., Sander C. The microRNA.org resource: targets and expression. Nucleic Acids Res. 2008, 36:D149-D153.
6. Ebert M.S., Neilson J.R., Sharp P.A. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat. Methods 2007, 4(9):721-726.
7. Tanzer A., Stadler P.F. Molecular evolution of a microRNA cluster. J. Mol. Biol. 2004, 339(2):327-335.
8. Olive V., Jiang I., He L. mir-17-92, a cluster of miRNAs in the midst of the cancer network. Int. J. Biochem. Cell Biol. 2010, 42(8):1348-1354.
9. Hayashita Y., Osada H., Tatematsu Y., Yamada H., Yanagisawa K., et al. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res. 2005, 65(21):9628-9632.
10. de Melo Maia B., Lavorato-Rocha A.M., Rodrigues L.S., Coutinho-Camillo C.M., Baiocchi G., et al. microRNA portraits in human vulvar carcinoma. Cancer Prev. Res. 2013, 6(11):1231-1241.
11. Messing M.J., Gallup D.G. Carcinoma of the vulva in young women. Obstet. Gynecol. 1995, 86:51-54.
12. Joura E.A., Losch A., Haider-Angeler M.G., Brei tenecker G., Leodolter S. Trends in vulvar neoplasia. Increasing incidence of vulvar intraepithelial neoplasia and squamous cell carcinoma of the vulva in young women. J. Reprod. 2000, 45:613-615.
13. Lanneau G.S., Argenta P.A., Lanneau M.S., Riffeburgh R.H., Gold M.A., et al. Vulvar cancer in young women: demographic features and outcome evaluation. Am. J. Obstet. Gynecol. 2009, 200:645.
14. Hørding U., Junge J., Daugaard S., Lundvall F., Poulsen H., et al. Vulvar squamous cell carcinoma and papillomaviruses: indications for two different etiologies. Gynecol. Oncol. 1994, 52:241-246.
15. Woelber L., Kock L., Gieseking F., Petersen C., Trillsch F., et al. Clinical management of primary vulvar cancer. Eur. J. Cancer 2011, 47(15):2315-2321.
16. Wills A., Obermair A. A review of complications associated with the surgical treatment of vulvar cancer. Gynecol. Oncol. 2013, 131(2):467-479.
17. Baiocchi G., Rocha R.M. Vulvar cancer surgery. Curr. Opin. Obstet. Gynecol. 2014, 26(1):9-17.
18. Kluiver J., Gibcus J.H., Hettinga C., Adema A., Richter M.K., et al. Rapid generation of microRNA sponges for microRNA inhibition. PloS One 2012, 7(1):e29275.
19. Pfaffl M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001, 29(9):e45.
20. Ebert M.S., Sharp P.A. MicroRNA sponges: progress and possibilities. RNA 2010, 16(11):2043-2050.
21. Otaegi G., Pollock A., Sun T. An optimized sponge for microRNA miR-9 affects spinal motor neuron development in vivo. Front. Neurosci. 2011, 5:146.
22. Kluiver J., Slezak-Prochazka I., Smigielska-Czepiel K., Halsema N., Kroesen B.J., et al. Generation of miRNA sponge constructs. Methods 2012, 58(2):113-117.
23. Kertesz M., Iovino N., Unnerstall U., Gaul U., Segal E. The role of site accessibility in microRNA target recognition. Nat. Genet. 2007, 39(10):1278-1284.
24. Long D., Lee R., Williams P., Chan C.Y., Ambros V., et al. Potent effect of target structure on microRNA function. Nat. Struct. Mol. Biol. 2007, 14(4):287-294.
25. Zhang S., Chen L., Jung E.J., Calin G.A. Targeting microRNAs with small molecules: from dream to reality. Clin. Pharmacol. Ther. 2010, 87(6):754-758.
26. Berindan-Neagoe I., Monroig Pdel C., Pasculli B., Calin G.A. MicroRNAome genome: a treasure for cancer diagnosis and therapy. CA Cancer J. Clin. 2014, 64(5):311-336.
27. Ling H., Fabbri M., Calin G.A. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat. Rev. Drug Discov. 2013, 12(11):847-865.
28. Ota A., Tagawa H., Karnan S., Tsuzuki S., Karpas A., et al. Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma. Cancer Res. 2004, 64(9):3087-3095.
29. Chang C.C., Yang Y.J., Li Y.J., Chen S.T., Lin B.R., et al. MicroRNA-17/20a functions to inhibit cell migration and can be used a prognostic marker in oral squamous cell carcinoma. Oral Oncol. 2013, 49(9):923-931.
30. Gao X., Zhang R., Qu X., Zhao M., Zhang S., et al. MiR-15a, miR-16-1 and miR-17-92 cluster expression are linked to poor prognosis in multiple myeloma. Leuk. Res. 2012, 36(12):1505-1509.
31. Yu G., Tang J.Q., Tian M.L., Li H., Wang X., et al. Prognostic values of the miR-17-92 cluster and its paralogs in colon cancer. J. Surg. Oncol. 2012, 106(3):232-237.
32. Wang Z., Wang B., Shi Y., Xu C., Xiao H.L., et al. Oncogenic miR-20a and miR-106a enhance the invasiveness of human glioma stem cells by directly targeting TIMP-2. Oncogene 2015, 12;34(11):1407-1419.
33. Li P., Xu Q., Zhang D., Li X., Han L., et al. Upregulated miR-106a plays an oncogenic role in pancreatic cancer. FEBS Lett. 2014, 588(5):705-712.
34. Qiang X.F., Zhang Z.W., Liu Q., Sun N., Pan L.L., et al. miR-20a promotes prostate cancer invasion and migration through targeting ABL2. J. Cell Biochem. 2014, 115(7):1269-1276.
35. Chang Y., Liu C., Yang J., Liu G., Feng F., et al. MiR-20a triggers metastasis of gallbladder carcinoma. J. Hepatol. 2013, 59(3):518-527.
36. Zhao S., Yao D., Chen J., Ding N. Circulating miRNA-20a and miRNA-203 for screening lymph node metastasis in early stage cervical cancer. Genet. Test. Mol. Biomark. 2013, 17(8):631-636.
37. Schmidt-Supprian M., Rajewsky K. Vagaries of conditional gene targeting. Nat. Immunol. 2007, 8:665-668.
38. Brown B.D., Naldini L. Exploiting and antagonizing microRNA regulation for therapeutic and experimental applications. Nat. Rev. Genet. 2009, 10(8):578-585.